Immuneering Corp (IMRX) stock
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.46−0.06 (-1.70%)
Close on Nov 17, 2026Market cap $224.08MP/E –Yield –
Immuneering revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Immuneering's revenue for the twelve months ending Dec 31, 2023 was $0, down 100.0% year over year. For fiscal 2023 it was $0, down 100.0% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $316.95K | -84.8% |
| FY2021 | Dec 31, 2021 | $2.08M | -10.0% |
| FY2020 | Dec 31, 2020 | $2.31M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $0 | -100.0% |
| Q1 FY2023 | Mar 31, 2023 | $0 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $455 | -99.8% |
| Q3 FY2022 | Sep 30, 2022 | $38.38K | -92.0% |
| Q2 FY2022 | Jun 30, 2022 | $94.42K | -85.7% |
| Q1 FY2022 | Mar 31, 2022 | $183.70K | -75.4% |
| Q4 FY2021 | Dec 31, 2021 | $189.59K | -71.5% |
| Q3 FY2021 | Sep 30, 2021 | $482.13K | -29.4% |
| Q2 FY2021 | Jun 30, 2021 | $660.04K | +37.3% |
| Q1 FY2021 | Mar 31, 2021 | $748.20K | – |
| Q4 FY2020 | Dec 31, 2020 | $665.08K | – |
| Q3 FY2020 | Sep 30, 2020 | $682.57K | – |
| Q2 FY2020 | Jun 30, 2020 | $480.84K | – |
See a number that looks wrong?